AI-driven multi-omics identifies SPP1⁺ tumor-associated macrophages as a therapeutic target and predicts lymph node metastasis in papillary thyroid cancer
Artificial intelligence (AI) is transforming drug design by enabling the systematic discovery of therapeutic targets and the prediction of drug response from complex biomedical data. In papillary thyroid carcinoma (PTC), lymph node metastasis remains a key determinant of poor outcome, yet targetable drivers and predictive models for metastasis are lacking. Here, we integrate single-cell RNA sequencing, spatial transcriptomics, and machine learning to identify SPP1⁺ tumor-associated macrophages (TAMs) as a functionally validated driver of lymph node metastasis in PTC. Using single-cell and spatial analyses, we show that SPP1⁺ TAMs engage TM4SF1⁺ malignant epithelial cells via the SPP1-CD44 axis within a hypoxic niche, driving tumor stemness, invasion, and metastatic progression. SPP1⁺ TAMs exhibit a hypoxic, M2-polarized phenotype and their abundance correlates with worse overall and progression‑free survival in metastatic PTC patients. We further develop an integrative machine-learning model based on SPP1⁺ TAM‑derived molecular features that predicts lymph node status with high accuracy. Preclinically, pharmacological targeting of SPP1 attenuates tumor cell migration, invasion, and lung metastasis, supporting its candidacy as a therapeutic target. Collectively, this study demonstrates how AI‑driven multi‑omics analysis can jointly identify a functionally validated target and generate a clinically deployable predictive model, illustrating a framework for bridging computational discovery with translational oncology.
Authors
- Yinde Huang (ORCID: https://orcid.org/0000-0002-6063-9549)
- Zhaokai Zhou (ORCID: https://orcid.org/0000-0001-6628-3750)
- 方申存
- Tianyu Zhao (ORCID: https://orcid.org/0000-0002-2696-273X)
- Weixiong Zhu (ORCID: https://orcid.org/0009-0009-7247-8111)
- Run Shi
- Jiaxuan Huai
- Shaohui Xu
- Xiqiao Zhou
- Jing Sun
- Yongjie Wang
- Yingjian Wang (ORCID: https://orcid.org/0009-0005-5928-1024)
- Jianpeng Zhang
Institutions
- Nanjing University of Chinese Medicine (CN)
- Chongqing University (CN)
- German Cancer Research Center (DE)
- Medical University of Graz (AT)
- Soochow University (CN)
- Nanjing Brain Hospital (CN)
- Lanzhou University Second Hospital (CN)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Nanjing Chest Hospital (CN)
- Second Xiangya Hospital of Central South University (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- First People's Hospital of Chongqing (CN)
- Nanjing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1038/s41698-026-01774-7
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chongqing Municipal Health Commission
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Science and Technology Planning Project of Yuzhong District of Chongqing City